The estimated Net Worth of Bros. Advisors Lp14159, L.P... is at least $2.27 Billion dollars as of 30 November 2018. Bros P owns over 11,764,705 units of Incyte stock worth over $2,271,224,222 and over the last 7 years Bros sold INCY stock worth over $0.
Bros has made over 7 trades of the Incyte stock since 2017, according to the Form 4 filled with the SEC. Most recently Bros bought 11,764,705 units of INCY stock worth $199,999,985 on 30 November 2018.
The largest trade Bros's ever made was exercising 20,316,327 units of Incyte stock on 15 March 2018 worth over $9,548,674. On average, Bros trades about 1,712,711 units every 17 days since 2017. As of 30 November 2018 Bros still owns at least 35,976,940 units of Incyte stock.
You can see the complete history of Bros P stock trades at the bottom of the page.
Over the last 21 years, insiders at Incyte have traded over $114,417,378 worth of Incyte stock and bought 24,211,970 units worth $713,884,116 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp667, L.P.B..., and Brothers Life Sciences Capi.... On average, Incyte executives and independent directors trade stock every 14 days with the average trade being worth of $4,355,654. The most recent stock trade was executed by Steven H Stein on 12 August 2024, trading 11,608 units of INCY stock currently worth $703,793.
incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. we have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. the incyte corporate headquarters is located in wilmington, delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders. for more information about incyte, please visit our corporate website at www.incyte.com.
Incyte executives and other stock owners filed with the SEC include: